Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:IPHANASDAQ:JYNTNASDAQ:MASS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeIPHAInnate Pharma$2.28-6.8%$2.00$1.29▼$3.51$190.71M0.27185,431 shs22,879 shsJYNTJoint$10.12+1.3%$10.87$9.58▼$17.82$155.07M1.5454,452 shs41,791 shsMASS908 Devices$5.73+2.0%$4.48$1.81▼$7.48$204.79M0.26981,181 shs459,312 shs10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceIPHAInnate Pharma-6.76%+1.56%+21.33%+18.49%-10.08%JYNTJoint+1.40%+2.22%-2.69%-12.46%-38.44%MASS908 Devices+1.78%+6.11%+36.10%+135.80%+0.53%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationIPHAInnate Pharma2.8119 of 5 stars3.85.00.00.02.01.70.0JYNTJoint3.2439 of 5 stars3.52.00.00.02.03.31.9MASS908 Devices0.874 of 5 stars1.32.00.00.02.03.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceIPHAInnate Pharma 3.50Strong Buy$11.00383.52% UpsideJYNTJoint 3.00Buy$15.5053.16% UpsideMASS908 Devices 2.50Moderate Buy$5.33-6.92% DownsideCurrent Analyst Ratings BreakdownLatest JYNT, MASS, and IPHA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/10/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)5/9/2025JYNTJointLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $16.004/24/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.004/24/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (D-) ➝ Sell (D-)4/8/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (D-)3/28/2025IPHAInnate PharmaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.50 ➝ $11.503/22/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/19/2025MASS908 DevicesWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 5/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookIPHAInnate Pharma$12.62M15.11N/AN/A$0.69 per share3.30JYNTJoint$51.90M2.99$0.65 per share15.65$1.68 per share6.02MASS908 Devices$59.63M3.43N/AN/A$5.11 per share1.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateIPHAInnate Pharma-$8.19MN/A0.00∞N/AN/AN/AN/AN/AJYNTJoint-$9.75M-$0.58N/A19.09N/A-13.95%8.24%2.33%N/AMASS908 Devices-$36.40M-$2.10N/AN/AN/A-109.11%-24.60%-19.23%5/13/2025 (Estimated)Latest JYNT, MASS, and IPHA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025MASS908 Devices-$0.29N/AN/AN/A$11.90 millionN/A5/8/2025Q1 2025JYNTJoint-$0.02-$0.03-$0.01$0.06$13.02 million$13.08 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthIPHAInnate PharmaN/AN/AN/AN/AN/AJYNTJointN/AN/AN/AN/AN/AMASS908 DevicesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioIPHAInnate Pharma0.922.92N/AJYNTJointN/A1.441.44MASS908 DevicesN/A4.243.54Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipIPHAInnate Pharma0.16%JYNTJoint76.88%MASS908 Devices88.06%Insider OwnershipCompanyInsider OwnershipIPHAInnate Pharma31.89%JYNTJoint27.90%MASS908 Devices27.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableIPHAInnate Pharma22083.83 million57.10 millionNot OptionableJYNTJoint32015.32 million10.46 millionOptionableMASS908 Devices6035.74 million25.18 millionOptionableJYNT, MASS, and IPHA HeadlinesRecent News About These CompaniesGranahan Investment Management LLC Decreases Position in 908 Devices Inc. (NASDAQ:MASS)May 13 at 6:54 AM | marketbeat.com908 Devices (NASDAQ:MASS) Given "Sell (D-)" Rating at Weiss RatingsMay 12 at 2:35 AM | marketbeat.comWeiss Ratings Reiterates Sell (D-) Rating for 908 Devices (NASDAQ:MASS)May 12 at 1:15 AM | americanbankingnews.com908 Devices (MASS) Expected to Announce Earnings on TuesdayMay 11 at 1:11 AM | americanbankingnews.com908 Devices Inc. (MASS): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 10 at 4:17 AM | finance.yahoo.com908 Devices Inc. (MASS): Among Nicholas J. Pritzker’s Stock Picks with Huge Upside PotentialMay 9, 2025 | insidermonkey.com908 Devices (MASS) to Release Quarterly Earnings on TuesdayMay 8, 2025 | marketbeat.com908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseMay 6, 2025 | zacks.comXTX Topco Ltd Buys Shares of 52,196 908 Devices Inc. (NASDAQ:MASS)May 2, 2025 | marketbeat.com908 Devices Equips rescEU Disaster Preparedness Reserve with Advanced Chemical DetectionApril 30, 2025 | finance.yahoo.comWhy 908 Devices Inc. (MASS) is Surging in 2025April 30, 2025 | insidermonkey.com56,310 Shares in 908 Devices Inc. (NASDAQ:MASS) Purchased by Bank of Montreal CanApril 28, 2025 | marketbeat.com908 Devices (NASDAQ:MASS) Receives "Sell (D-)" Rating from Weiss RatingsApril 27, 2025 | marketbeat.comLeerink Partners Remains a Hold on 908 Devices (MASS)April 24, 2025 | markets.businessinsider.comMasivo Announces Drill Program at Cerro ColoradoApril 24, 2025 | newsfilecorp.comBuy 4 Low-Beta Stocks ANIP, LRN, MASS & CTGO as Tariff Woes ContinueApril 23, 2025 | zacks.com908 Devices Receives $2M Order from the Texas Department of Public Safety for Drug Detection and MitigationApril 22, 2025 | 01net.it908 Devices reports preliminary Q1 revenue $11.5M. consensus $11.9MApril 16, 2025 | markets.businessinsider.com908 Devices Announces Preliminary First Quarter 2025 Financial ResultsApril 15, 2025 | finance.yahoo.com908 Devices expects Q1 revenue below estimatesApril 15, 2025 | msn.com908 Devices Leads These 3 Penny Stocks To ConsiderApril 10, 2025 | uk.finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Why D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumGold Rally Continues: These 3 Mining Stocks Are Likely to BenefitBy Chris Markoch | April 16, 2025View Gold Rally Continues: These 3 Mining Stocks Are Likely to BenefitWhy Institutions Are Buying Super Micro Computer Stock AgainBy Gabriel Osorio-Mazilli | April 28, 2025View Why Institutions Are Buying Super Micro Computer Stock AgainSeismic Shift at Intel: Massive Layoffs Precede Crucial EarningsBy Jeffrey Neal Johnson | April 24, 2025View Seismic Shift at Intel: Massive Layoffs Precede Crucial EarningsJYNT, MASS, and IPHA Company DescriptionsInnate Pharma NASDAQ:IPHA$2.28 -0.17 (-6.76%) Closing price 05/12/2025 03:58 PM EasternExtended Trading$2.33 +0.05 (+2.37%) As of 04:14 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Innate Pharma S.A., a biotechnology company, develops immunotherapies for cancer patients in France and internationally. The company's products include Lacutamab (IPH4102), an anti-KIR3DL2 antibody, which is in Phase II clinical trials for the treatment of cutaneous T-cell and peripheral T-cell lymphoma, as well as in Phase II clinical trials to treat refractory sézary syndrome; Monalizumab, an immune checkpoint inhibitor that is in Phase III clinical trial to treat advanced solid tumors comprising colorectal and lung cancer, as well as head and neck cancer; IPH5201, a blocking antibody that is in Phase II clinical trials targeting the CD39 immunosuppressive pathway; IPH5301, an anti-CD73 antibody targeting the immunosuppressive adenosine pathway to promote antitumor immunity; IPH6401, an BCMA-targeting NK cell engager; and IPH6101, a NKp46-based NK cell engager that targets CD123 proprietary multi-specific antibody format; and IPH62, an B7-H3-targeting NK cell engager. Its products in preclinical trials are IPH43, an anti-MICA/B ADC and IPH45, an antibody drug conjugates (ADC); and IPH67, an undisclosed, multi-specific ANKET. The company has licensing and collaboration agreements with AstraZeneca, Novo Nordisk A/S, Sanofi, and Orega Biotech; and co-development and license agreement with MedImmune Limited. Innate Pharma S.A. was incorporated in 1999 and is headquartered in Marseille, France.Joint NASDAQ:JYNT$10.12 +0.13 (+1.30%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$10.29 +0.17 (+1.69%) As of 05:06 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.908 Devices NASDAQ:MASS$5.73 +0.11 (+1.96%) Closing price 05/12/2025 04:00 PM EasternExtended Trading$5.64 -0.09 (-1.48%) As of 07:07 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.908 Devices Inc., a commercial-stage technology company, provides various purpose-built handheld and desktop mass spectrometry devices to interrogate unknown and invisible materials in life sciences research, bioprocessing, pharma/biopharma, forensics, and adjacent markets. The company's products include MX908, a handheld, battery-powered, and Mass Spec device that is designed for rapid analysis of solid, liquid, vapor, and aerosol materials of unknown identity; Rebel, a small desktop analyzer that provides real-time information on the extracellular environment in bioprocesses; and Maverick, an optical in-line analyzer that offers real-time monitoring and control of multiple bioprocess parameters, including glucose, lactate, and total biomass in mammalian cell cultures, as well as provides process fingerprint data to support large-scale efforts in predictive bioprocess modeling. Its products also comprise Maven and Trace C2, an online device for bioprocess monitoring and control; and ZipChip solution, a plug-and-play, high-resolution separation platform that optimizes Mass Spec sample analysis. The company operates in the United States, Europe, the Middle East, Africa, the Asia Pacific, and rest of the Americas. 908 Devices Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Latest Deal Could Put a Freeze on Its Stock Price A 90-Day Tariff Pause Sends Alibaba Flying—BlackRock Was Ready Why DraftKings Share Price Could Soar to Multi-Year Highs BP Buyout Buzz Puts Spotlight on Transocean’s Comeback Potential Here's Why Call Option Traders Love Dutch Bros Stock Can Shopify Stock Make a Comeback After an Earnings Sell-Off? MarketBeat Week in Review – 05/05 - 05/09 Taiwan Semiconductor Has a New Reason to Rally on Chip Curbs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
